Biotech Co.*
(Country; Symbol)

Pharma Co.
(Country)

Product

Terms/Details (Date)


Access Pharmaceuticals Inc. (AMEX:AKC)

GlaxoSmithKline
plc (UK)

Amlexanox to treat mucosal and skin disorders

Access gets U.S. marketing rights to amlexanox 5% paste, and the remaining worldwide marketing rights covered under a prior licensing agreement between the companies; Access will make an initial payment, additional payments over time and milestone payments based on commercial successes (7/23)

Atrix
Laboratories

Inc.
(ATRX)

Key
Oncologists Ltd.

Eligard

Agreement is for the South African market- ing rights to Eligard prostate cancer products; Key Oncologists will be responsible for all required regulatory sub- missions (9/3)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Bruno Farmaceutici
SpA (Italy)

Avanir's docosanol
10% cream

The agreement gives Bruno rights to manufacture and market in Italy the cream as a treatment for cold sores; Avanir will receive an up-front licensing payment and potential milestone payments, as well as royalties (8/5)

BioMimetic Pharmaceuticals Inc.*

Orthovita Inc.

Resorbable beta-tricalcium phosphate scaffold

BioMimetic will use its recombinant human platelet-derived growth factor in combination with Orthovita's Vitomatrix particulate synthetic scaffold biomaterial; Orthovita will manufacture and supply the scaffold to BioMimetic for its clinical and commercial use in conjunction with rhPDGF (8/21)

Cell Pathways
Inc.
(CLPA)

John O. Butler
Co.

Gelclair Concentrated Oral Gel for oral pain

Butler will market Gelclair to the dental market within the U.S., as well as in Canada upon approval (8/21)

DrugAbuse
Sciences Inc.*

Laureate Pharma
LP

Naltrexone depot

Laureate will provide manufacturing services for naltrexone, a sustained-release microsphere product (6/24)

Enzon Inc.
(ENZN)

Aventis SA
(France)

Oncaspar

Enzon will conduct all marketing and sales activities for the U.S., Mexico, Canada and the Asia/Pacific region (7/1)

Epoch
Biosciences
Inc.
(EBIO)

Amersham
Biosciences (division of Amersham plc; UK)

MGB Eclipse Probe
Systems

Amersham will become the exclusive worldwide sales and marketing partner of Epoch's MGB Eclipse Probe Systems for the research field (7/30)

InKine Pharmaceutical Company Inc. (INKP)

Global Damon
Pharm (Korea)

Visicol

Licensing agreement for exclusive rights to Visicol in Korea; Global Damon will register Visicol as a bowel-cleansing agent; InKine will receive an up-front license fee and potential milestone and royalty payments (9/17)

Ista Pharmaceuticals
Inc.
(ISTA)

Cardinal Health
Inc.

Vitrase

Cardinal Health will manufacture commercial quantities of Vitrase, as well as perform certain quality control tests for territories, including the U.S., Canada, Japan and the European Union (7/9)

LumiCyte Inc.*

Shimadzu Corp.
(Japan)

SELDI-based protein mapping services

Shimadzu will market and distribute the services in Japan; the deal is for five years and has a value of more than $30M (6/24)

NicOx SA
(France; Nouveau Marche:NICOX)

Axcan Pharma Inc.
(Canada)

NCX 1000

Axcan obtained an exclusive license to commercialize NCX 1000 to treat chronic liver diseases, including portal hypertension and hepatitis C, in Poland and Canada, as well as an option to acquire rights for the U.S. market; Axcan will pay NicOx $500,000 and options or milestones that could total $18.5M; if approved, Axcan would pay royalties of up to 12% (5/23)

Orphan
Medical Inc.*

Express Scripts
Inc.

Xyrem (sodium oxybate) oral solution

Express Scripts became the sole distributor of the Xyrem oral solution (8/23)

Personal
Chemistry
AB*
(Sweden)

Amersham Biosciences KK (Japan; subsidiary
of Amersham Biosciences)

Coherent Synthesis chemistry automation platform and its related knowledge management system, Emrys Knowledge Builder

Distribution agreement giving Amersham sole Japanese distribution rights for the products (7/24**)

Phyton Inc.*

Bristol-Myers
Squibb Co.

Paclitaxel

Multimillion-dollar deal for the supply of paclitaxel; Phyton will receive up-front cash payments, manufacturing revenues, annual license fees and royalties (7/10)

Serono SA
(Switzerland; NYSE:SRA)

Pfizer Inc.

Rebif

Agreement to co-promote the multiple sclerosis drug Rebif in the U.S.; Pfizer gave Serono a $200M up-front fee; companies will share all commercialization and development costs (7/11)

StemCells Inc.
(STEM)

BioWhittaker
Inc. (subsidiary
of Cambrex Corp.)

Human neural stem
cells

BioWhittaker will manufacture, use and sell certain human neural stem cells for educational and research purposes; financial terms were not disclosed (6/28)

TolerRx Inc.*

Laureate Pharma
LP

TolerRx's therapeutic monoclonal antibody pipeline

The agreement is a manufacturing and services agreement in which Laureate Pharma will provide purification and asceptic filling services to support TolerRx's clinical trials (8/20)


Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies. Some items occurred before June 20 but were not listed in the previous chart.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

** Denotes the date the item ran in BioWorld International.

AMEX = American Stock Exchange; NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange